Breast Cancer, HER2-positive Breast Cancer, Sentinel Lymph Node, Triple Negative Breast Cancer
Conditions
Keywords
Neoadjuvant Chemotherapy, Sentinel lymph node biopsy, Breast cancer, Complete response
Brief summary
This study evaluates whether SLNB can safely be omitted in breast cancer patients with HER2+ or TN tumors who achieve a radiological complete response on MRI after neoadjuvant systemic therapy
Detailed description
Axillary staging in clinically node negative (cN0) breast cancer patients with neoadjuvant systemic therapy (NST; i.e. chemo- and immunotherapy), is preferably performed with sentinel lymph node biopsy (SLNB) after NST. The probability of a tumor-positive SLNB post-NST is low. cN0 patients with Human Epidermal growth factor Receptor 2- positive (HER2+) or triple negative (TN) breast cancer who achieve radiologic complete response (rCR) of the breast on MRI, have the lowest probability of a tumor-positive SLNB post-NST (\<3%). Omitting removal of axillary lymph nodes in clinically node negative patients does not increase the rate of distant metastases nor breast cancer mortality. Performing SLNB can cause short- and long-term morbidity, reducing quality of life. The additional value of performing SLNB in patients with a very low risk of tumor-positive axillary lymph nodes should be investigated.
Interventions
No sentinel lymph node biopsy will be performed in clinically node-negative triple-negative or HER2-positive breast cancer patients with a radiologic complete response on MRI. Participants will be asked to complete quality of life questionnaires at baseline (prior to surgery), 6 months, 1, 3 and 5 years follow-up. A control group consisting of 100 clinically node-negative patients receiving standard treatment will be used to compare QoL scores. This group consists of patients that do not wish to participate in the experimental group (i.e., no sentinel node lymph node biopsy) or patients that are not eligible.
Sponsors
The Netherlands Cancer Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Prospective non-inferiority cohort, single-arm registration trial
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Women, aged ≥ 18 years * Invasive HER2+ (HR+/-) or TN breast cancer * Primary tumor (T), clinical stage T1-3 * Neoadjuvant systemic therapy (NST), at least 3 cycles * Tumor stage assessed with breast MRI before start NST * Clinically node-negative before start NST (no suspect ALNs on ultrasound and FGD-PET/CT, or negative cyto-/histopathology in case of suspect nodes) * MRI after or during NST shows radiologic complete response * Written and signed informed consent
Exclusion criteria
* Primary tumor (T) clinical stage T4 * Patients without ultrasound or FDG-PET/CT pre-NST * History of breast cancer ipsilateral breast * Synchronous contralateral breast cancer * Synchronous M1 disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Axillary recurrence | at 5 years | To show that sentinel lymph node biopsy after neoadjuvant systemic therapy can be omitted in clinically node-negative HER2+ or TN breast cancer patients who achieve radiological complete response on MRI without compromising the 5 - year axillary recurrence rate (i.e, \< 6% axillary recurrences within 5 years). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Level of cancer worry | at 5 years | To compare study participants in whom sentinel lymph node biopsy is omitted to patients with sentinel lymph node biopsy on level of cancer worry, using the cancer worry scale (CWS). The CWS consists of 8 items, with 1-4 points per item and a maximum score of 32 points. Higher scores indicate more frequent cancer worry. |
| Recurrence-free survival | at 5 years | To assess 5-year recurrence-free survival in clinically node-negative HER2+ or TN patients with radiologic complete response on MRI in whom sentinel lymph node biopsy is omitted. |
| Overall survival | at 5 years | To assess 5-year overall survival in clinically node-negative HER2+ or TN patients with radiologic complete response on MRI in whom sentinel lymph node biopsy is omitted. |
| Disease-specific survival | at 5 years | To assess 5-year disease specific survival in clinically node-negative HER2+ or TN patients with radiologic complete response on MRI in whom sentinel lymph node biopsy is omitted. |
| Breast cancer specific quality of life | at 5 years | To compare study participants in whom sentinel lymph node biopsy is omitted to patients with sentinel lymph node biopsy on breast cancer related quality of life, especially axillary morbidity score. This is measured with the EORTC-BR23 scale. The arm morbidity score consists of 3 items, points ranging from 1 - 4 per item. A higher score indicates more morbidity. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Survival by pathological response | at 5 years | To assess 5-year survival in patients with and without a pathological complete response |
| Recurrence rate by pathological response | at 5 years | To assess 5-year recurrence-free survival in patients with and without a pathological complete response |
| Axillary recurrence rate by pathological response | at 5 years | To assess 5-year axillary recurrence-free survival in patients with and without a pathological complete response |
Contacts
Primary ContactMarie-Jeanne T.F.D. Vrancken Peeters, MD, PhD
Backup ContactFrederieke H. van Duijnhoven, MD, PhD
Outcome results
None listed